

1 ***Cladosporium* species recovered from clinical samples in the United**
2 **States**

3
4 RUNNING TITLE: *Cladosporium* from clinical samples

5
6 Authors: Marcelo Sandoval-Denis¹, Deanna A. Sutton², Adela Martin-Vicente¹,
7 José F. Cano-Lira¹, Nathan Wiederhold², Josep Guarro¹, Josepa Gené^{1#}

8
9 ¹ Unitat de Micologia, Facultat de Medicina i Ciències de la Salut, IISPV,
10 Universitat Rovira i Virgili, Reus, Spain.

11 ² Fungus Testing Laboratory, University of Texas Health Science Center, San
12 Antonio, Texas.

13
14 KEYWORDS: Mould infections, *Cladosporium*, *Capnodiales*, antifungal
15 susceptibility testing, fungi.

16
17 WORD COUNT: ABSTRACT: 221

18 TEXT: 3337

19
20 # Corresponding author.

21 Mailing address: Unitat de Micologia, Facultat de Medicina, Universitat Rovira i
22 Virgili, Carrer Sant Llorenç, 21. 43201. Reus, Spain. E-mail: josepa.

23 gene@urv.cat

24

25 **ABSTRACT**

26 *Cladosporium* species are ubiquitous, saprobic dematiaceous fungi, only
27 infrequently associated with human and animal opportunistic infections. We
28 have studied a large set of *Cladosporium* isolates recovered from clinical
29 samples in the USA to ascertain the predominant species in that country, in light
30 of recent taxonomic changes in this genus, and to determine if some could
31 possibly be rare potential pathogens. A total of 92 isolates were identified using
32 phenotypic and molecular methods, which included sequence analysis of the
33 internal transcribed spacer (ITS) region, and a fragment of the large subunit
34 (LSU) of the nuclear ribosomal DNA, as well as fragments of the translation
35 elongation factor 1 alpha (*EF-1 α*) and actin (*Act*) genes. The most frequent
36 species was *Cladosporium halotolerans* (14.8%), followed by *C. tenuissimum*
37 (10.2%), *C. subuliforme* (5.7%) and *C. pseudocladosporioides* (4.5%).
38 However, 39.8 % of the isolates did not correspond to any known species
39 comprising at least 17 new lineages for *Cladosporium*. The most frequent
40 anatomic site of isolation was the respiratory tract (54.5%), followed by
41 superficial (28.4%) and deep tissues and fluids (14.7%). Species of the two
42 recently described cladosporium-like genera, *Toxicocladosporium* and
43 *Penidiella*, are reported for the first time from clinical samples. *In vitro*
44 susceptibility testing of 92 isolates against nine antifungal drugs showed
45 variable results, but with a high overall activity for the azoles, echinocandins
46 and terbinafine.

47

48

49

50 **INTRODUCTION**

51 *Cladosporium* species are among the most common fungal inhabitants
52 worldwide, being isolated from almost any environmental source and
53 geographic location (1). The genus is characterized by the typical form of its
54 conidiophores, which are erect, straight or geniculate, producing abundant
55 branched acropetal chains of smooth to roughened dry conidia, showing a
56 distinct darkened coronate hilum, i.e, conidial scar characterized by a thick rim
57 surrounding a central convex dome (2, 3). The relatively small conidia are easily
58 detached and disseminated by the wind, *Cladosporium* being one of the most
59 frequently isolated air-borne fungi (2, 4).

60 The most common *Cladosporium* species are primarily isolated from soil
61 and plant material, where they are frequently encountered as saprobes or
62 secondary invaders on follicular lesions, concomitant with other plant
63 pathogenic fungi (1, 5, 6). However, several species are important pathogens of
64 plants and some are also able to affect animals including humans (7-9).
65 *Cladosporium* is usually associated with allergic rhinitis (10) or localized
66 superficial or deep lesions (11-14), but rarely can cause disseminated infections
67 (7, 15-17).

68 The genus *Cladosporium* has been shown to be both morphologically
69 and phylogenetically heterogeneous (18). On the basis of molecular data, the
70 true human-pathogenic species *C. bantiana*, *C. carrionii* and *C. devriesii*,
71 characterized by their thermotolerance and the absence of conidiophores with
72 pigmented conidial scars, were transferred to *Cladophialophora* (1, 7, 18). More
73 recently, *Cladosporium* underwent extensive revisions based on polyphasic
74 approaches (1, 3, 19-21), which resulted in the delimitation of 169 species

75 currently accepted in *Cladosporium* sensu stricto (*Cladosporiaceae*,
76 *Capnodiales*). On the other hand, a great number of taxa were excluded from
77 that genus, now being considered as doubtful species or accommodated into
78 several related new genera such as *Hyalodendriella*, *Ochrocladosporium*,
79 *Rachicladosprium*, *Rhizocladosprium*, *Toxicocladosprium* and
80 *Verrucocladosprium* (1, 3).

81 The diversity of *Cladosporium* associated with human disease is
82 currently reduced to four species, i.e., *C. cladosporioides*, *C. herbarum*, *C.*
83 *oxysporum* and *C. sphaerospermum* (7). Most of these data, however, are
84 based on a reduced number of clinical cases with the identification of the
85 etiological agents not confirmed by using reliable methods. Moreover, three of
86 the clinically relevant species: *C. cladosporioides*, *C. herbarum* and *C.*
87 *sphaerospermum* have been demonstrated to be species complexes (19-21),
88 encompassing several morphologically sibling species only distinguished by
89 means of phylogenetic analyses (1, 7). The clinical significance of these
90 phylogenetic species, however, has yet to be evaluated (22).

91 The objective of this work was to assess the diversity of *Cladosporium*
92 species associated with human and animal disease by analysing a large set of
93 isolates from clinical specimens by means of phenotypic and DNA sequence
94 data analyses. In addition, the *in vitro* susceptibility of these isolates was
95 evaluated against nine clinically available antifungal drugs.

96

97 **MATERIALS AND METHODS**

98 **Fungal isolates.** A total of 92 isolates tentatively identified as *Cladosporium*
99 spp. were included in this study (Table 1). All of the isolates were obtained from

100 human and animal clinical specimens, mostly from the United States, received
101 in the Fungus Testing Laboratory at the University of Texas Health Science
102 Center at San Antonio (UTHSC) from different parts of the country mainly for
103 identification purposes.

104 **Phenotypic identification.** The isolates were morphologically characterized
105 following the procedures outlined in Bensch et al. (1), Crous et al. (23),
106 Schubert et al. (19), and Zalar et al. (20). Briefly, all of the isolates were grown
107 on Synthetic Nutrient-Poor Agar (SNA; KH_2PO_4 1 g, KNO_3 1 g, $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$
108 0.5 g, KCl 0.5 g, glucose 0.2 g, sucrose 0.2 g, water 1L) and Potato Dextrose
109 Agar (PDA: Pronadisa, Spain) for 7d at 25 °C. Microscopic observations were
110 made from cultures on SNA mounted in Shear's solution (23). Colony
111 characteristics were recorded from cultures on SNA and PDA. For the
112 estimation of cardinal growth temperatures, the isolates were grown on PDA
113 agar for 14d at temperatures ranging from 15 °C to 35 °C at intervals of 5 °C,
114 and 37 °C.

115 **DNA extraction, amplification and sequencing.** Total genomic DNA was
116 extracted from mycelia obtained from colonies growing on PDA, using FastPrep
117 (MP Biomedicals, Santa Ana, California, USA) following the manufacturer's
118 protocol. DNA was quantified using Nanodrop 3000 (Thermo Scientific, Madrid,
119 Spain).

120 The primers ITS5 and ITS4 (24) were used to amplify a region spanning
121 the internal transcribed spacers (ITS) 1 and 2 and the 5.8S gene of the rRNA,
122 the primers pairs LR0R/LR5 (25, 26) were used to amplify a fragment of the
123 LSU gene of the rRNA, and the EF-728F/EF-986R and ACT-512F/ACT-783R

124 primers (27) were used for the translation elongation factor 1- α gene (*EF-1 α*)
125 and the actin gene (*Act*), respectively.

126 Sequencing was performed in both directions using the same PCR
127 primers at Macrogen Europe (Macrogen Inc. Amsterdam, the Netherlands).
128 Consensus sequences were obtained using SeqMan version 7.0.0 (DNASStar
129 Lasergene, Madison, WI, USA).

130 **Molecular identification and phylogenetic analyses.** An initial presumptive
131 generic identification of the isolates was performed based on BLAST searches
132 of ITS and LSU sequences in the GenBank (<http://www.ncbi.nlm.nih.gov/>) and
133 CBS (<http://www.cbs.knaw.nl/>) databases. Multiple sequence alignments of
134 each locus were performed in MEGA version 6 (28) using the ClustalW
135 application (29), refined with MUSCLE (30), and manually adjusted if
136 necessary. Phylogenetic reconstructions were made using maximum-likelihood
137 (ML) and Bayesian Inference (BI) under MEGA version 6 and MrBayes version
138 3.1.2 (31), respectively. The best nucleotide substitution model (GTR+G+I for
139 the three independent datasets) was estimated using MrModelTest version 2.3
140 (32) following the Akaike criterion. Phylogenetic analyses using ML were at first
141 made individually for each locus and compared in order to assess for any
142 incongruent results between nodes with high statistical support. As no
143 incongruences were observed, the four loci were combined as follows: ITS, *EF-*
144 *1 α* and *Act* for members of *Cladosporium* sensu stricto and ITS combined with
145 LSU for members of other cladosporium-like genera. For the ML analysis,
146 nearest-neighbour interchange (NNI) was used as the heuristic method for tree
147 inference. Support for the internal branches was assessed by a search of 1,000
148 bootstrapped sets of data. A bootstrap support (bs) of ≥ 70 was considered

149 significant. For BI analysis, two simultaneous runs of 10,000,000 generations
150 were performed and samples were stored every 1,000 generations. The 50%
151 majority-rule consensus tree and posterior probability values (pp) were
152 calculated after discarding the first 25% of the samples. A pp value ≥ 0.95 was
153 considered significant.

154 The first combined phylogenetic analysis with ITS, *EF-1 α* and *Act*
155 sequences of clinical isolates belonging to *Cladosporium* sensu stricto and all
156 the available type and reference strains was carried out following the
157 alignments of Bensch et al. (1) (data not shown). Only sequences of those
158 species closely related (>95% similarity) with the clinical isolates tested here
159 were included in the final analysis.

160 **Antifungal Susceptibility.** The antifungal susceptibility test was performed
161 according to the CLSI M38-A2 standard (33) with slight modifications. The
162 incubation temperature was set to 25 °C given the optimal growth requirements
163 of *Cladosporium* and related taxa (1, 33). Nine antifungal agents were tested:
164 amphotericin B (AMB), 5-fluorocytosine (5FC), itraconazole (ITC),
165 posaconazole (PSC), voriconazole (VRC), terbinafine (TRB), anidulafungin
166 (AFG), caspofungin (CFG) and micafungin (MFG). The minimal effective
167 concentration (MEC), defined as the lowest drug concentration at which short,
168 stubby, highly branched hyphae were observed, was determined at 24 h for the
169 echinocandins, and the minimal inhibitory concentration (MIC) was determined
170 at 48 h for the remaining drugs. The MIC was defined as the lowest
171 concentration exhibiting 100% visual inhibition of growth for AMB, ITC, PSC and
172 VRC, or 50% and 80% reduction in growth for 5FC and TRB, respectively.
173 *Paecilomyces variotii* ATCC MYA-3630 and *Aspergillus fumigatus* ATCC MYA-

174 3626 were used as quality control strains. Statistical analyses of the MIC/MEC
175 data were performed using the Mann-Whitney test in Prism version 6.0
176 (GraphPad Software, San Diego, CA).

177 **Nucleotide sequence accession numbers.** DNA sequences determined in
178 this study were deposited in GenBank under accession numbers LN834353 to
179 LN834448 (rDNA), LN834449 to LN834536 (*EF-1 α*) and LN834537 to
180 LN834624 (*Act*) (Table 1).

181

182 **RESULTS**

183 Analysis of ITS and LSU sequences showed that 88 isolates (96%) belonged to
184 *Cladosporium sensu stricto*, three isolates (3%) to the genus
185 *Toxicocladosporium* and one isolate (1%) to the genus *Penidiella*.

186 The phylogenetic analysis of *Cladosporium sensu stricto* included 121
187 taxa and 1,002 bp (ITS 447 bp, *EF-1 α* 337 bp and *Act* 218 bp) from which 485
188 bp were constant (ITS 347 bp, *EF-1 α* 60 bp and *Act* 78 bp), 496 were variable
189 (ITS 97 bp, *EF-1 α* 260 bp and *Act* 139 bp) and 328 were parsimony informative
190 (ITS 24 bp, *EF-1 α* 197 bp and *Act* 107 bp) (Fig 1). The majority of isolates (57,
191 65%) nested into the *C. cladosporioides* complex: 28 belonged to nine species
192 (i.e., *C. angustisporum*, *C. asperulatum*, *C. cladosporioides*, *C. flabelliforme*, *C.*
193 *funiculosum*, *C. perangustum*, *C. pseudocladosporioides*, *C. subuliforme* and *C.*
194 *tenuissimum*), while 29 isolates clustered into 12 terminal sub-clades genetically
195 distant to any currently known species of the genus. A total of 14 isolates were
196 related to the *C. herbarum* complex (16%), mostly corresponding to five species
197 (i.e., *C. allicinum*, *C. herbarum*, *C. macrocarpum*, *C. ramotenellum*, and *C.*
198 *subinflatum*), while five isolates clustered into four new lineages in the genus.

199 Seventeen isolates were nested within the *C. sphaerospermum* complex (19%)
200 and mostly belonged to two species (i.e., *C. halotolerans* and *C.*
201 *sphaerospermum*), while a single isolate represented a new lineage.

202 Distinct morphological features of isolates in the *C. cladosporioides*
203 complex included the formation of mostly unbranched, cylindrical conidiophores,
204 bearing ovoidal to ellipsoidal intercalary and terminal conidia, smooth or rarely
205 showing fine ornamentation (Fig. 2 a-c); the maximum temperature for growth
206 was 32 °C for *C. cladosporioides*, *C. flabelliforme*, *C. perangustum* and *C.*
207 *pseudocladosporioides*; and 35 °C for *C. angustisporum*, *C. funiculosum*, *C.*
208 *subuliforme* and *C. tenuissimum*. Isolates of the *C. herbarum* complex exhibited
209 mostly nodulose conidiophores, bearing distinctly ornamented globose to
210 subglobose terminal conidia (Fig. 2 d-f); none of the isolates of this complex
211 were able to grow at temperatures above 32 °C, while *C. allicinum* exhibited a
212 maximum growth temperature of 30 °C. Isolates of the *C. sphaerospermum*
213 complex formed cylindrical and branched conidiophores, bearing globose to
214 subglobose conidia, smooth or finely ornamented (Fig. 2 g-i); the maximum
215 temperature for growth was 32 °C for *C. sphaerospermum* and 35 °C for *C.*
216 *halotolerans*. None of the clinical isolates formed sexual morphs in culture.

217 Overall, the most commonly identified species was *C. halotolerans*
218 (14.8%), followed by *C. tenuissimum* (10.2%) and *C. subuliforme* (5.7%).
219 However, 39.8 % did not match with any known taxa, representing at least 17
220 putative new *Cladosporium* species (Fig. 1). The most common anatomical site
221 of isolation was the respiratory tract (54.5%), mainly from bronchoalveolar
222 lavage fluid (BAL) and nasal specimens, followed by superficial sites (28.4%);

223 these percentages were similar for all the identified species and species
224 complexes.

225 Phylogenetic analysis of the *Toxicocladosporium* isolates included 15
226 taxa and 984 bp (LSU 530 bp, ITS 454 bp) from which 826 bp were constant
227 (LSU 464 bp and ITS 362 bp), 155 were variable (LSU 66 bp and ITS 89 bp)
228 and 129 were parsimony informative (LSU 56 bp and ITS 73 bp) (Fig 3). Two
229 clinical isolates belonged to *T. irritans*, while the isolate UTHSC DI-13-172
230 formed an independent lineage, genetically related to *T. strelitziae*, but showing
231 distinctive morphological features and probably corresponding to a new
232 species. The main morphological characteristics of members of
233 *Toxicocladosporium* were the presence of non-nodulose conidiophores with
234 dark and thickened cell walls and septa, producing conidia without the typical
235 coronate scars of *Cladosporium* (Fig. 2 j-l), and a maximum temperature for
236 growth of 35 °C.

237 According to the LSU sequence analysis, a single isolate (UTHSC DI-13-
238 256), originally identified as *C. sphaerospermum*, was related to but distant
239 (<98.2% sequence similarity) from members of the genus *Penidiella* (i.e., *P.*
240 *aggregata* and *P. drakensbergensis*, sequence accession numbers JF499862
241 and KC005792, respectively) (data not shown). However, its final identification
242 was not possible given the scarcity of DNA sequences of the latter species for
243 comparison. This isolate was characterized by restricted growth (3-4 mm at 25
244 °C for 7d) and the production of solitary penicillate conidiophores, composed of
245 chains of ramoconidia with slightly pigmented and thickened conidiogenous
246 scars.

247 Results of the antifungal susceptibility testing are summarized in Table 2.
248 Overall results for *Cladosporium* species showed a geometric mean (GM) MIC
249 and MIC₉₀ values for AMB of 0.64 µg/ml and 2 µg/ml, respectively. Among the
250 azoles, ITC and PSC were the most active, both drugs with a GM MIC of 0.43
251 µg/ml and a MIC₉₀ of 0.5 µg/ml and 1 µg/ml, respectively; while VRC showed a
252 GM MIC and MIC₉₀ of 1.68 µg/ml and 4 µg/ml, respectively. Flucytosine showed
253 variable activity with a GM MIC and MIC₉₀ of 1.37 µg/ml and 4 µg/ml,
254 respectively. TRB exhibited the most potent activity with a GM MIC and MIC₉₀ of
255 0.09 µg/ml and 1 µg/ml, respectively. With the exception of CFG, the
256 echinocandins exhibited strong *in vitro* activity with GM MIC values of 0.19
257 µg/ml and 0.12 µg/ml for AFG and MFG. All of the *Cladosporium* species tested
258 showed similar susceptibility patterns except for *C. sphaerospermum*, where the
259 three isolates tested exhibited higher MIC and MEC values, especially for the
260 azoles, AMB, AFG and MFG (P<0.001). Comparison of antifungal susceptibility
261 by species complex (Table 3) showed that AMB exhibited more potent activity
262 against members of the *C. herbarum* complex with GM MIC and MIC₉₀ values of
263 0.18 µg/ml and 1 µg/ml (P<0.002), while members of *C. sphaerospermum*
264 complex exhibited higher GM MIC and MIC₉₀ values for AMB, PSC, ITC and
265 CSP (P<0.003). *Toxicocladosporium* and *Penidiella* isolates exhibited similar
266 susceptibility patterns mostly with low GM MIC and MIC₉₀ values against all
267 antifungals tested but without statistically significant differences.

268

269 DISCUSSION

270 Members of *Cladosporium* are relatively easy to identify to genus and species
271 complex based on their typical conidiogenous structures. However,

272 morphological identification of *Cladosporium* species is difficult given the high
273 morphological similarity between closely related species. In light of our results, it
274 is strongly recommended that the phenotypic identification be confirmed with
275 DNA sequencing. Several authors have demonstrated the usefulness of *EF-1 α*
276 and *Act* loci to allow a good species delimitation in *Cladosporium* (1, 19, 21).
277 This is especially important for members of the *C. cladosporioides* complex,
278 which demonstrated the greatest species diversity, the highest number of
279 species associated with clinical samples, and also the greatest number of
280 undescribed species. Moreover, we found that *C. cladosporioides*, the species
281 most frequently cited as being clinically relevant, was poorly represented in our
282 set of isolates, while *C. asperulatum*, *C. funiculosum*, *C. flabelliforme*, *C.*
283 *pseudocladosporioides*, *C. subuliforme* and *C. tenuissimum* are described from
284 the first time from clinical samples. Similarly, in the *C. sphaerospermum*
285 complex, most of the isolates morphologically identified as *C. sphaerospermum*
286 were genetically reidentified as belonging to the phenotypically similar species
287 *C. halotolerans*, which according to our data, emerged as the most common
288 species from clinical origin. The latter species has never been associated with
289 human infection; however, some isolates had been reported from human or
290 animal clinical samples (1). In the case of the *C. herbarum* complex, 13 of the
291 14 isolates morphologically identified as *C. herbarum*, also considered a
292 clinically relevant species, were found to belong to other species of this complex
293 (i.e., *C. allicinum*, *C. macrocarpum* and *C. ramotenellum*). While *C.*
294 *macrocarpum* has been identified as the causative agent of human infections
295 (17), *C. allicinum* and *C. ramotenellum* never have been reported before in the
296 clinical setting, although some isolates have been recorded as obtained from

297 human samples (1). However, due to the lack of clinical histories and
298 histopathological findings, it was impossible for us to confirm the pathogenic
299 role of the species reported here for the first time from clinical specimens.

300 It is remarkable that our phylogenetic analysis was unable to identify a
301 high number of *Cladosporium* isolates at the species level (39.8%), which were
302 originally considered as belonging to several common morphospecies. Instead,
303 those unidentified isolates were grouped into 5 terminal clades and 12
304 monotypic lineages, representing a high variety of phylogenetic species. It is
305 probable that many of these clades and monotypic lineages represent new
306 species, however further studies combining phenotypic and molecular data
307 would be necessary to confirm these findings. We report also for the first time
308 the isolation of *Toxicocladosporium* and *Penidiella* species from clinical
309 specimens. Isolates of such recently proposed genera were only known from
310 leafs of several plants and environmental sources (3, 34). According to our
311 data, the vast majority of isolates were obtained from respiratory specimens,
312 including BAL, nasal and sputum samples. This is not rare, because
313 *Cladosporium* is preponderant in the air-borne mycobiota (35), being
314 considered as one of the most important respiratory allergenic fungi, after
315 *Alternaria* (10, 34, 36).

316 Reports of invasive infections by *Cladosporium* are extremely rare. Bentz
317 & Sautter (37) reported a mixed disseminated infection by *Aspergillus fumigatus*
318 and *C. cladosporioides* in an immunocompromised patient. *Cladosporium*
319 *cladosporioides* and *C. macrocarpum* have been reported from two clinical
320 cases involving the central nervous system (15, 17), while *C. sphaerospermum*
321 was isolated from an intrabronchial infection (38). However, in none of these

322 cases was the etiology of the infection supported by histopathological studies.
323 The isolation of *Cladosporium* species from deep tissues seems improbable
324 considering the inability of these organisms to growth at temperatures
325 exceeding 35 °C, and thermotolerance being one of the most important
326 virulence factors for invasive or disseminated infections (39). In our study less
327 than half of the isolates exhibited very limited growth at 35 °C, while none was
328 able to grow at 37 °C. However, surprisingly, several of our isolates were
329 obtained from deep tissue samples, including bone marrow, CSF, lung and
330 lymphatic tissue, among others. Isolation of these fungi from invasive infections
331 may have been due to environmental contamination of the samples, however
332 occasionally isolates that fail to grow in culture at 37 °C have been reported to
333 cause invasive disease in compromised individuals (40).

334 There is a paucity of information regarding antifungal susceptibility
335 patterns for *Cladosporium* species. Most data are from a few reported clinical
336 cases (7, 13, 15, 41). Our study provides the first *in vitro* data for a large set of
337 clinical isolates including several species obtained from diverse anatomical sites
338 and not previously reported from clinical samples. Case reports have shown a
339 favourable outcome using azole-based therapies. ITC has shown efficacy in the
340 treatment of superficial infections caused by *C. cladosporioides*, *C.*
341 *sphaerospermum* and *C. oxysporum* (8, 14, 37, 41-44), while VRC was effective
342 against *C. macrocarpum* in a brain abscess (17). This agrees with our *in vitro*
343 data that demonstrated that the azoles, particularly ITC and PSC, have good
344 activity against *Cladosporium* species, although VRC displayed variable activity.
345 AMB has shown to be ineffective against *C. cladosporioides* (41) and *C.*
346 *sphaerospermum* (38) in cases of skin and intrabronchial infections,

347 respectively. Our results, however, suggest that this drug might be effective,
348 especially against members of the *C. herbarum* complex. Kantarcioğlu & Yücel
349 (45) reported potent *in vitro* activity of TRB against a set of unidentified
350 *Cladosporium* species. Our data confirmed the results of that study, with TRB
351 showing significant activity against all the species tested. Echinocandin activity
352 against *Cladosporium* species has not been previously evaluated, however we
353 observed that both AFG and MFG exhibited notable *in vitro* activity against all of
354 our isolates, and could represent an important alternative for the treatment of
355 infections by these fungi pending further confirmatory studies.

356 In conclusion, our study has significantly expanded the diversity of
357 *Cladosporium* species seen in clinical specimens as a result of the molecular
358 characterization of these isolates. We were unable, however, to document
359 these organisms as etiologic agents in human or animal disease due to the lack
360 of clinical information and/or histopathological findings. It is also important to
361 note that most reported cases of *Cladosporium* infections lack molecular
362 confirmation, and in those cases where they have been so characterized, the
363 strains are not available. Given that many journals require the public availability
364 of DNA sequence data, we recommend that clinical strains be deposited in
365 international culture collections, thereby making them available for re-
366 identification and further study.

367

368 **ACKNOWLEDGMENTS**

369 This study was supported by the Spanish Ministerio de Economía y
370 Competitividad, grants CGL2011-27185 and CGL2013-43789-P.

371

372 **REFERENCES**

- 373 **1. Bensch K, Braun U, Groenewald JZ, Crous PW.** 2012. The genus
374 *Cladosporium*. *Stud. Mycol.* **72**:1–401.
- 375 **2. David JC.** 1997. A contribution to the systematics of *Cladosporium*. Revision
376 of the fungi previously referred to *Heterosporium*. *Mycol. Pap.* **172**:1–157.
- 377 **3. Crous PW, Braun U, Schubert K, Groenewald JZ.** 2007. Delimiting
378 *Cladosporium* from morphologically similar genera. *Stud. Mycol.* **58**:33–56.
- 379 **4. Ellis D, Davis S, Alexiou H, Handke R, Bartley R (ed),** 2007. Descriptions
380 of medical fungi, second edition. Underdale, South Australia: Nexus Print
381 Solutions.
- 382 **5. Ellis MB.** 1971. Dematiaceous hyphomycetes. CMI, Kew.
- 383 **6. Ellis MB.** 1976. More dematiaceous hyphomycetes. CMI, Kew.
- 384 **7. de Hoog GS, Guarro J, Gené J, Figueras MJ.** 2011. Atlas of clinical fungi.
385 CD-ROM version 3.1, CBS-KNAW fungal biodiversity centre, Utrecht.
- 386 **8. Ma X, Gu Y, Liu X, Li D, Ling S, Hou J, Wang C, Cao S, Huang X, Wen X,**
387 **Ruan J, Dong C, Li C, Tong Y.** 2013. Phaeohyphomycotic dermatitis in a giant
388 panda (*Ailuropoda melanoleuca*) caused by *Cladosporium cladosporioides*.
389 *Med. Mycol. Case Rep.* **2**:119–121.
- 390 **9. Mercier E, Peters IR, Billen F, Battaille G, Clercx C, Day MJ, Peeters D.**
391 2013. Potential role of *Alternaria* and *Cladosporium* species in canine
392 lymphoplasmacytic rhinitis. *J. Small Anim. Pract.* **54**:179–183.
- 393 **10. Sellart-Altisent M, Torres-Rodríguez JM, Gómez de Ana S, Alvarado-**
394 **Ramírez E.** 2007. Nasal fungal microbiota in allergic and healthy subjects. *Rev.*
395 *Iberoam. Micol.* **24**:125–130. (Article in Spanish)

- 396 **11. Drabick JJ, Gomatos PJ, Solis JB.** 1990. Cutaneous cladosporiasis as a
397 complication of skin testing in a man positive for human immunodeficiency
398 virus. *J. Am. Acad. Dermatol.* **22**:135–136.
- 399 **12. Gugnani HC, Sood N, Singh B, Makkar R.** 2000. Case Report.
400 Subcutaneous phaeohyphomycosis due to *Cladosporium cladosporioides*.
401 *Mycoses* **43**:85–87.
- 402 **13. Gugnani HC, Ramesh V, Sood N, Guarro J, Moin-UI-Haq, Paliwal-Joshi**
403 **A, Singh B.** 2006. Cutaneous phaeohyphomycosis caused by *Cladosporium*
404 *oxysporum* and its treatment with potassium iodide. *Med. Mycol.* **44**:285–288.
- 405 **14. Sang H, Zheng XE, Zhou WQ, He W, Lv GX, Shen YN, Kong QT, Liu**
406 **WD.** 2012. A case of subcutaneous phaeohyphomycosis caused by
407 *Cladosporium cladosporioides* and its treatment. *Mycoses.* **55**:195–197.
- 408 **15. Kantarcioğlu AS, Yücel A, de Hoog GS.** 2002. Case report. Isolation of
409 *Cladosporium cladosporioides* from cerebrospinal fluid. *Mycoses.* **45**:11–12.
- 410 **16. Kantarcioğlu AS, de Hoog GS.** 2003. Infections of the central nervous
411 system by melanized fungi: a review of cases presented between 1999 and
412 2004. *Mycoses.* **47**:4–13.
- 413 **17. Lalueza A, López-Medrano F, del Palacio A, Alhambra A, Alvarez E,**
414 **Ramos A, Pérez A, Lizasoain M, Meije Y, García-Reyne A, Aguado JM.**
415 2011. *Cladosporium macrocarpum* brain abscess after endoscopic ultrasound-
416 guided celiac plexus block. *Endoscopy.* **43**:E9–E10.
- 417 **18. de Hoog GS, Guého E, Masclaux F, Gerrits van den Ende AH, Kwon-**
418 **Chung KJ, McGinnis MR.** 1995. Nutritional physiology and taxonomy of
419 human-pathogenic *Cladosporium-Xylohypha* species. *Med. Mycol.* **33**:339–347.

- 420 **19. Schubert K, Groenewald JZ, Braun U, Dijksterhuis J, Starink M, Hill CF,**
421 **Zalar P, de Hoog GS, Crous PW.** 2007. Biodiversity in the *Cladosporium*
422 *herbarum* complex (Davidiellaceae, Capnodiales), with standardisation of
423 methods for *Cladosporium* taxonomy and diagnostics. *Stud. Mycol.* **58**:105–
424 156.
- 425 **20. Zalar P, de Hoog GS, Schroers HJ, Crous PW, Groenewald JZ, Gunde-**
426 **Cimerman N.** 2007. Phylogeny and ecology of the ubiquitous saprobe
427 *Cladosporium sphaerospermum*, with descriptions of seven new species from
428 hypersaline environments. *Stud. Mycol.* **58**:157–183.
- 429 **21. Bensch K, Groenewald JZ, Dijksterhuis J, Starink-Willemse M,**
430 **Andersen B, Summerell BA, Shin HD, Dugan FM, Schroers HJ, Braun U,**
431 **Crous PW.** 2010. Species and ecological diversity within the *Cladosporium*
432 *cladosporioides* complex (Davidiellaceae, Capnodiales). *Stud. Mycol.* **67**:1–94.
- 433 **22. de Hoog GS, Chaturvedi V, Denning DW, Dyer PS, Frisvad JC, Geiser**
434 **D, Gräser Y, Guarro J, Haase G, Kwon-Chung KJ, Meis JF, Meyer W, Pitt**
435 **JI, Samson RA, Taylor JW, Tintelnot K, Vitale RG, Walsh TJ, Lackner M;**
436 **ISHAM working group on Nomenclature of Medical Fungi.** 2014. Name
437 changes in medically important fungi and their implications for clinical practice.
438 *J. Clin. Microbiol.* **53**:1056–1062.
- 439 **23. Crous PW, Verkley GJM, Groenewald JZ, Samson RA (ed).** 2009. Fungal
440 Biodiversity. CBS Laboratory Manual Series 1: 1–269. Centraalbureau voor
441 Schimmelcultures, Utrecht, Netherlands.
- 442 **24. White TJ, Bruns T, Lee S, Taylor JW.** 1990. Amplification and direct
443 sequencing of fungal ribosomal RNA genes for phylogenetics, p 315–322. In

- 444 Innis MA, Gelfand DH, Sninsky JJ, White TJ (ed), PCR protocols: a guide to
445 methods and applications. Academic Press, New York, NY.
- 446 **25. Vilgalys R, Hester M.** 1990. Rapid genetic identification and mapping of
447 enzymatically amplified ribosomal DNA from several *Cryptococcus* species. J.
448 Bacteriol. **172**:4238–4246.
- 449 **26. Rehner SA, Samuels GJ.** 1994. Taxonomy and phylogeny of *Gliocladium*
450 analyzed from nuclear large subunit ribosomal DNA sequences. Mycol. Res.
451 **98**: 625–634.
- 452 **27. Carbone I, Kohn LM.** 1999. A method for designing primer sets for
453 speciation studies in filamentous ascomycetes. Mycologia **91**:553–556.
- 454 **28. Tamura K, Stecher G, Peterson D, Filipinski A, Kumar S.** 2013. MEGA6:
455 Molecular Evolutionary Genetics Analysis version 6.0. Mol. Biol. Evol. **30**:2725–
456 2729.
- 457 **29. Thompson JD, Higgins DG, Gibson TJ.** 1994. CLUSTAL W: improving the
458 sensitivity of progressive multiple sequence alignment through sequence
459 weighting, position-specific gap penalties and weight matrix choice. Nucleic
460 Acids Res. **22**:4673–4680.
- 461 **30. Edgar RC.** 2004. MUSCLE: multiple sequence alignment with high
462 accuracy and high throughput. Nucleic Acids Res. **32**:1792–1797.
- 463 **31. Huelsenbeck JP, Ronquist F.** 2001. MrBayes: Bayesian inference of
464 phylogenetic trees. Bioinformatics **17**:754 –755.
- 465 **32. Nylander JA.** 2004. MrModeltest v2. Evolutionary Biology Centre, Uppsala
466 University, Uppsala, Sweden.
- 467 **33. Clinical and Laboratory Standards Institute.** 2008. Reference method for
468 broth dilution antifungal susceptibility testing of filamentous fungi; approved

- 469 standard—2nd ed. Document M38-A2. Clinical and Laboratory Standards
470 Institute, Wayne, PA.
- 471 **34. Crous PW, Groenewald JZ.** 2011. Why everlastings don't last. *Persoonia*
472 **26**:70–84.
- 473 **35. de Ana SG, Torres-Rodríguez JM, Ramírez EA, García SM, Belmonte-**
474 **Soler J.** 2006. Seasonal distribution of *Alternaria*, *Aspergillus*, *Cladosporium*
475 and *Penicillium* species isolated in homes of fungal allergic patients. *J. Investig.*
476 *Allergol. Clin. Immunol.* **16**:357–363.
- 477 **36. Torras MA, Artigas JG, Fernandez GS.** 1981. Air-borne fungi in the air of
478 Barcelona (Spain). IV. The genus *Cladosporium*. *Mycopathologia.* **74**:19–24.
- 479 **37. Bentz MS, Sautter RL.** 1993. Disseminated infection with *Aspergillus*
480 *fumigatus* and *Cladosporium cladosporioides* in an immunocompromised host.
481 *Abstr. Gen. Meet. ASM* **93**:533.
- 482 **38. Yano S, Koyabashi K, Kato K.** 2003. Intrabronchial lesion due to
483 *Cladosporium sphaerospermum* in a healthy, non-asthmatic woman. *Mycoses.*
484 **46**:348–350.
- 485 **39. Seyedmousavi S, Guillot J, de Hoog G.S.** 2013. Phaeohyphomycoses,
486 emerging opportunistic diseases in animals *Clin. Microbiol. Rev.* **26**:19–35.
- 487 **40. Tucker DL, Beresford CH, Sigler L, Rogers K.** 2004. Disseminated
488 *Beauveria bassiana* infection in a patient with acute lymphoblastic leukemia. *J.*
489 *Clin. Microbiol.* **42**:5412-5414.
- 490 **41. Vieira MR, Milheiroy A, Pacheco FA.** 2001. Phaeohyphomycosis due to
491 *Cladosporium cladosporioides*. *Med. Mycol.* **39**:135–137.

- 492 **42. Romano C, Bilenchi R, Alessandrini C, Miracco C.** 1999. Case report.
493 Cutaneous phaeohyphomycosis caused by *Cladosporium oxysporum*.
494 *Mycoses*. **42**:111–115.
- 495 **43. Duquia RP, de Almeida HL Jr, Vettorato G, Rocha NM, de Castro LA.**
496 2010. Ecthyma-like phaeohyphomycosis caused by *Cladosporium*
497 *cladosporioides*. *Mycoses*. **53**:541-543.
- 498 **44. Sosa EE, Cohen PR, Tschen JA.** 2012. *Cladosporium* scalp infection.
499 *Skinmed*. **10**:393–394.
- 500 **45. Kantarcioğlu AS, Yücel A.** 2002. In-vitro activities of terbinafine,
501 itraconazole and amphotericin B against *Aspergillus* and *Cladosporium* species.
502 *J Chemother*. **14**:562–567.

503 **Table 1** Clinical isolates, type or reference strains and sequences included in this study.

| Species | Strain/Isolate number | Origin (Country) | GenBank accession N° | | | |
|-------------------------------------|-------------------------|---|----------------------|----------|-----------------|-----------------|
| | | | ITS | LSU | EF-1 α | Act |
| <i>Cercospora beticola</i> | CBS 116456 ^T | <i>Beta vulgaris</i> (Italy) | NR121315 | GU214404 | AY840494 | AY840458 |
| <i>Cercospora olivascens</i> | CBS 253.67 ^T | Unknown | NR111773 | - | | |
| <i>Cladosporium allicinum</i> | CBS 121624 ^T | <i>Hordeum vulgare</i> (Belgium) | EF679350 | - | EF679425 | EF679502 |
| | UTHSC DI-13-173 | Human, lung (USA) | LN834353 | - | LN834449 | LN834537 |
| | UTHSC DI-13-176 | Human, skin (USA) | LN834354 | - | LN834450 | LN834538 |
| <i>Cladosporium angustisporum</i> | UTHSC DI-13-266 | Canine, skin (USA) | LN834355 | - | LN834451 | LN834539 |
| | CBS 125983 ^T | <i>Alloxylon wickhamii</i> (Australia) | HM147995 | - | HM148236 | HM148482 |
| <i>Cladosporium asperulatum</i> | UTHSC DI-13-240 | Human, toe nail (USA) | LN834356 | - | LN834452 | LN834540 |
| | CBS 126339 | <i>Eucalyptus</i> leaf litter (India) | HM147997 | - | HM148238 | HM148484 |
| | CBS 126340 ^T | <i>Protea susannae</i> (Portugal) | HM147998 | - | HM148239 | HM148485 |
| <i>Cladosporium cladosporioides</i> | UTHSC DI-13-216 | Feline, nasal (USA) | LN834357 | - | LN834453 | LN834541 |
| | CBS 101367 | Soil (Brasil) | HM148002 | - | HM148243 | HM148489 |
| | CBS 112388 ^T | Indoor air (Germany) | HM148003 | - | HM148244 | HM148490 |
| | UTHSC DI-13-204 | Human, abdomen (USA) | LN834358 | - | LN834454 | LN834542 |
| | UTHSC DI-13-209 | Human, pleural (USA) | LN834359 | - | LN834455 | LN834543 |
| <i>Cladosporium colocasiae</i> | UTHSC DI-13-215 | Human, sputum (USA) | LN834360 | - | LN834456 | LN834544 |
| | CBS 386.64 ^T | <i>Colocasia antiquorum</i> (Taiwan) | HM148067 | - | HM148310 | HM148555 |
| | CBS 119542 | <i>Colocasia esculanta</i> (Taiwan) | HM148066 | - | HM148309 | HM148554 |
| <i>Cladosporium cucumerinum</i> | CBS 171.52 ^T | Fruit of <i>Cucumis sativus</i> (Netherlands) | HM148072 | - | HM148316 | HM148561 |
| | CBS 173.54 | Fruit of <i>Cucumis sativus</i> (Netherlands) | HM148074 | - | HM148318 | HM148563 |
| <i>Cladosporium flabelliforme</i> | CBS 126345 ^T | <i>Melaleuca cajuputi</i> (Australia) | HM148092 | - | HM148336 | HM148581 |
| <i>Cladosporium funiculosum</i> | UTHSC DI-13-267 | Human, sputum (USA) | LN834361 | - | LN834457 | LN834545 |
| | CBS 122128 | Unknown | HM148093 | - | HM148337 | HM148582 |
| | CBS 122129 ^T | Leaf of <i>Vigna umbellata</i> (Japan) | HM148094 | - | HM148338 | HM148583 |
| | UTHSC DI-13-175 | Human, BAL (USA) | LN834362 | - | LN834458 | LN834546 |

| | | | | | | | |
|---|---------------------------------|---------------------------------------|--------------------------------------|-----------------|-----------------|-----------------|-----------------|
| | UTHSC DI-13-223 | Human, BAL (USA) | LN834363 | - | LN834459 | LN834547 | |
| | UTHSC DI-13-242 | Human, nasal wash (USA) | LN834364 | - | LN834460 | LN834548 | |
| <i>Cladosporium halotolerans</i> | CBS 119416 ^T | Hypersaline water (Namibia) | DQ780364 | - | JN906989 | EF101397 | |
| | FMR 13493 | Human, unknown (Spain) | LN834365 | - | LN834461 | LN834549 | |
| | UTHSC DI-13-164 | Human, bone marrow (USA) | LN834366 | - | LN834462 | LN834550 | |
| | UTHSC DI-13-182 | Marine mammal, dermis (USA) | LN834367 | - | LN834463 | LN834551 | |
| | UTHSC DI-13-183 | Human, bronchus (USA) | LN834368 | - | LN834464 | LN834552 | |
| | UTHSC DI-13-206 | Human, BAL (USA) | LN834369 | - | LN834465 | LN834553 | |
| | UTHSC DI-13-213 | Human, lymph node (USA) | LN834370 | - | LN834466 | LN834554 | |
| | UTHSC DI-13-221 | Human, bone marrow (USA) | LN834371 | - | LN834467 | LN834555 | |
| | UTHSC DI-13-231 | Catheter tip (USA) | LN834372 | - | LN834468 | LN834556 | |
| | UTHSC DI-13-249 | Human, nasal (USA) | LN834373 | - | LN834469 | LN834557 | |
| | UTHSC DI-13-250 | Human, scalp (USA) | LN834374 | - | LN834470 | LN834558 | |
| | UTHSC DI-13-252 | Human, toe nail (USA) | LN834375 | - | LN834471 | LN834559 | |
| | UTHSC DI-13-259 | Human, BAL (USA) | LN834376 | - | LN834472 | LN834560 | |
| | UTHSC DI-13-263 | Human, BAL (USA) | LN834377 | - | LN834473 | LN834561 | |
| | <i>Cladosporium herbaroides</i> | CBS 121626 ^T | Hypersaline water (Israel) | EF679357 | - | EF679432 | EF679509 |
| | <i>Cladosporium herbarum</i> | CBS 121621 ^T | <i>Hordeum vulgare</i> (Netherlands) | EF679363 | - | EF679440 | EF679516 |
| | | UTHSC DI-13-220 | Human, BAL (USA) | LN834378 | - | LN834474 | LN834562 |
| <i>Cladosporium iranicum</i> | CBS 126346 ^T | Leaf of <i>Citrus sinensis</i> (Iran) | HM148110 | - | HM148354 | HM148599 | |
| <i>Cladosporium iridis</i> | CBS 138.40 ^T | Leaf of <i>Iris</i> sp. (Netherlands) | EF679370 | - | EF679447 | EF679523 | |
| <i>Cladosporium macrocarpum</i> | CBS 121623 ^T | <i>Spinacia oleracea</i> (USA) | EF679375 | - | EF679453 | EF679529 | |
| | UTHSC DI-13-191 | Human, face (USA) | LN834379 | - | LN834475 | LN834563 | |
| <i>Cladosporium oxysporum</i> | CBS 125991 | Soil (China) | HM148118 | - | HM148362 | HM148607 | |
| | CBS 126351 | Indoor air (Venezuela) | HM148119 | - | HM148363 | HM148608 | |
| <i>Cladosporium perangustum</i> | CBS 125996 ^T | <i>Cussonia</i> sp. (South Africa) | HM148121 | - | HM148365 | HM148610 | |
| | UTHSC DI-13-208 | Canine, BAL (USA) | LN834380 | - | LN834476 | LN834564 | |
| <i>Cladosporium pseudocladosporioides</i> | CBS 117153 | Leaf of <i>Paeonia</i> sp. (Germany) | HM148157 | - | HM148401 | HM148646 | |
| | CBS 125993 ^T | Outside air (Netherlands) | HM148158 | - | HM148402 | HM148647 | |
| | UTHSC DI-13-187 | Turtle, unknown (USA) | LN834381 | - | LN834477 | LN834565 | |

| | | | | | | |
|------------------------------------|-------------------------|--|-----------------|---|-----------------|-----------------|
| | UTHSC DI-13-232 | Human, shoulder (USA) | LN834382 | - | LN834478 | LN834566 |
| | UTHSC DI-13-233 | Human, BAL (USA) | LN834383 | - | LN834479 | LN834567 |
| | UTHSC DI-13-261 | Human, sputum (USA) | LN834384 | - | LN834480 | LN834568 |
| <i>Cladosporium ramotenellum</i> | CBS 121628 ^T | Hypersaline water (Slovenia) | EF679384 | - | EF679462 | EF679538 |
| | UTHSC DI-13-166 | Human, nasal tissue (USA) | LN834385 | - | LN834481 | LN834569 |
| | UTHSC DI-13-222 | Animal, Nasal (USA) | LN834386 | - | LN834482 | LN834570 |
| | UTHSC DI-13-224 | Animal, Nasal (USA) | LN834387 | - | LN834483 | LN834571 |
| <i>Cladosporium sinuosum</i> | CBS 121629 ^T | <i>Fuchsia excorticata</i> (New Zealand) | EF679386 | - | EF679464 | EF679540 |
| <i>Cladosporium sphaerospermum</i> | CBS 193.54 ^T | Human, nail (Netherlands) | DQ780343 | - | EU570261 | EU570269 |
| | UTHSC DI-13-184 | Frog, abscess (USA) | LN834388 | - | LN834484 | LN834572 |
| | UTHSC DI-13-229 | Human, BAL (USA) | LN834389 | - | LN834485 | LN834573 |
| | UTHSC DI-13-237 | Human, BAL (USA) | LN834390 | - | LN834486 | LN834574 |
| <i>Cladosporium subinflatum</i> | CBS 121630 ^T | Hypersaline water (Slovenia) | EF679389 | - | EF679467 | EF679543 |
| | UTHSC DI-13-189 | Human, toe nail (USA) | LN834391 | - | LN834487 | LN834575 |
| <i>Cladosporium subtilissimum</i> | CBS 113754 ^T | Grape berry (USA) | EF679397 | - | EF679475 | EF679551 |
| <i>Cladosporium subuliforme</i> | CBS 126500 ^T | <i>Chamaedorea metallica</i> (Thailand) | HM148196 | - | HM148441 | HM148686 |
| | UTHSC DI-13-171 | Human, CSF (USA) | LN834392 | - | LN834488 | LN834576 |
| | UTHSC DI-13-180 | Human, BAL (USA) | LN834393 | - | LN834489 | LN834577 |
| | UTHSC DI-13-214 | Human, BAL (USA) | LN834394 | - | LN834490 | LN834578 |
| | UTHSC DI-13-254 | Human, BAL (USA) | LN834395 | - | LN834491 | LN834579 |
| | UTHSC DI-13-255 | Human, toe nail (USA) | LN834396 | - | LN834492 | LN834580 |
| <i>Cladosporium tenuissimum</i> | CBS 125995 ^T | Fruits of <i>Lagerstroemia</i> sp. (USA) | HM148197 | - | HM148442 | HM148687 |
| | UTHSC DI-13-174 | Marine mammal, lung (USA) | LN834397 | - | LN834493 | LN834581 |
| | UTHSC DI-13-177 | Human, skin (USA) | LN834398 | - | LN834494 | LN834582 |
| | UTHSC DI-13-188 | Human, BAL (USA) | LN834399 | - | LN834495 | LN834583 |
| | UTHSC DI-13-205 | Human, BAL (USA) | LN834400 | - | LN834496 | LN834584 |
| | UTHSC DI-13-236 | Human, nasal (USA) | LN834401 | - | LN834497 | LN834585 |
| | UTHSC DI-13-239 | Human, sputum (USA) | LN834402 | - | LN834498 | LN834586 |
| | UTHSC DI-13-253 | Human, BAL (USA) | LN834403 | - | LN834499 | LN834587 |

| | | | | | | |
|-------------------------|-----------------|----------------------------------|----------|---|----------|----------|
| | UTHSC DI-13-258 | Human, thoracentesis fluid (USA) | LN834404 | - | LN834500 | LN834588 |
| | UTHSC DI-13-274 | Human, toe (USA) | LN834405 | - | LN834501 | LN834589 |
| <i>Cladosporium</i> sp. | UTHSC DI-13-165 | Human, arm drainage (USA) | LN834406 | - | LN834502 | LN834590 |
| | UTHSC DI-13-168 | Human, BAL (USA) | LN834407 | - | LN834503 | LN834591 |
| | UTHSC DI-13-169 | Human, BAL (USA) | LN834408 | - | LN834504 | LN834592 |
| | UTHSC DI-13-170 | Human, toe nail (USA) | LN834409 | - | LN834505 | LN834593 |
| | UTHSC DI-13-178 | Animal, abscess (USA) | LN834410 | - | LN834506 | LN834594 |
| | UTHSC DI-13-179 | Human, hand (USA) | LN834411 | - | LN834507 | LN834595 |
| | UTHSC DI-13-190 | Human, CSF (USA) | LN834412 | - | LN834508 | LN834596 |
| | UTHSC DI-13-207 | Human, CSF (USA) | LN834413 | - | LN834509 | LN834597 |
| | UTHSC DI-13-210 | Human, skin (USA) | LN834414 | - | LN834510 | LN834598 |
| | UTHSC DI-13-211 | Human, BAL (USA) | LN834415 | - | LN834511 | LN834599 |
| | UTHSC DI-13-212 | Human, ethmoid sinus (USA) | LN834416 | - | LN834512 | LN834600 |
| | UTHSC DI-13-217 | Human, nasal (USA) | LN834417 | - | LN834513 | LN834601 |
| | UTHSC DI-13-218 | Human, BAL (USA) | LN834418 | - | LN834514 | LN834602 |
| | UTHSC DI-13-219 | Human, foot (USA) | LN834419 | - | LN834515 | LN834603 |
| | UTHSC DI-13-225 | Animal, BAL (USA) | LN834420 | - | LN834516 | LN834604 |
| | UTHSC DI-13-226 | Human, BAL (USA) | LN834421 | - | LN834517 | LN834605 |
| | UTHSC DI-13-227 | Human, sputum (USA) | LN834422 | - | LN834518 | LN834606 |
| | UTHSC DI-13-228 | Human, foot skin (USA) | LN834423 | - | LN834519 | LN834607 |
| | UTHSC DI-13-234 | Human, sputum (USA) | LN834424 | - | LN834520 | LN834608 |
| | UTHSC DI-13-235 | Human, BAL (USA) | LN834425 | - | LN834521 | LN834609 |
| | UTHSC DI-13-238 | Human, leg (USA) | LN834426 | - | LN834522 | LN834610 |
| | UTHSC DI-13-241 | Human, foot (USA) | LN834427 | - | LN834523 | LN834611 |
| | UTHSC DI-13-244 | Human, BAL (USA) | LN834428 | - | LN834524 | LN834612 |
| | UTHSC DI-13-245 | Human, toe (USA) | LN834429 | - | LN834525 | LN834613 |
| | UTHSC DI-13-246 | Human, BAL (USA) | LN834430 | - | LN834526 | LN834614 |
| | UTHSC DI-13-247 | Human, BAL (USA) | LN834431 | - | LN834527 | LN834615 |
| | UTHSC DI-13-251 | Human, BAL (USA) | LN834432 | - | LN834528 | LN834616 |

| | | | | | | |
|--|-------------------------|--|-----------------|-----------------|-----------------|-----------------|
| | UTHSC DI-13-257 | Human, sputum (USA) | LN834433 | - | LN834529 | LN834617 |
| | UTHSC DI-13-262 | Dolphin, bronchus (USA) | LN834434 | - | LN834530 | LN834618 |
| | UTHSC DI-13-265 | Human, BAL (USA) | LN834435 | - | LN834531 | LN834619 |
| | UTHSC DI-13-268 | Human, toe nail (USA) | LN834436 | - | LN834532 | LN834620 |
| | UTHSC DI-13-269 | Human, BAL (USA) | LN834437 | - | LN834533 | LN834621 |
| | UTHSC DI-13-270 | Human, nail (USA) | LN834438 | - | LN834534 | LN834622 |
| | UTHSC DI-13-271 | Human, BAL (USA) | LN834439 | - | LN834535 | LN834623 |
| | UTHSC DI-13-273 | Human, toe nails (USA) | LN834440 | - | LN834536 | LN834624 |
| <i>Cladosporium variabile</i> | CBS 121636 ^T | <i>Spinacia oleracea</i> (USA) | EF679402 | - | EF679480 | EF679556 |
| <i>Penidiella</i> sp. | UTHSC DI-13-256 | Human, nail (USA) | LN834441 | LN834445 | - | - |
| <i>Toxicocladosporium banksiae</i> | CBS 128215 ^T | Leaf of <i>Banksia emulata</i> (Australia) | HQ599598 | HQ599599 | - | - |
| <i>Toxicocladosporium chlamydosporum</i> | CBS 124157 ^T | Leaf of <i>Eucalyptus camaldulensis</i> (Madagascar) | FJ790283 | FJ790301 | - | - |
| <i>Toxicocladosporium ficiniae</i> | CBS 136406 ^T | Leaf of <i>Ficinia</i> sp. (South Africa) | KF777190 | KF777241 | - | - |
| <i>Toxicocladosporium irritans</i> | CBS 185.58 ^T | Mouldy paint (Suriname) | EU040243 | EU040243 | - | - |
| | UTHSC DI-13-181 | Human, blood (USA) | LN834442 | LN834446 | - | - |
| | UTHSC DI-13-230 | Human, finger nail (USA) | LN834443 | LN834447 | - | - |
| <i>Toxicocladosporium pini</i> | CBS 138005 ^T | Needles of <i>Pinus</i> sp. (China) | KJ869160 | KJ869217 | - | - |
| <i>Toxicocladosporium posoqueriae</i> | CBS 133583 ^T | Leaf of <i>Posoqueria latifolia</i> (Australia) | NR121555 | KC005803 | - | - |
| <i>Toxicocladosporium protearum</i> | CBS 126499 ^T | Leaf of <i>Protea burchellii</i> (South Africa) | HQ599586 | HQ599587 | - | - |
| <i>Toxicocladosporium pseudoveloxum</i> | CBS 128775 ^T | Leaf of <i>Phaenocoma prolifera</i> (South Africa) | JF499847 | JF499867 | - | - |
| <i>Toxicocladosporium rubrigenum</i> | CBS 124158 ^T | Leaf of <i>Eucalyptus camaldulensis</i> (Madagascar) | FJ790287 | FJ790305 | - | - |
| <i>Toxicocladosporium</i> sp. | UTHSC DI-13-172 | Human, BAL (USA) | LN834444 | LN834448 | - | - |
| <i>Toxicocladosporium strelitziae</i> | CBS 132535 ^T | Leaf of <i>Strelitzia reginae</i> (South Africa) | NR111765 | JX069858 | - | - |
| <i>Toxicocladosporium veloxum</i> | CBS 124159 ^T | Leaf of <i>Eucalyptus camaldunensis</i> (Madagascar) | FJ790288 | FJ790306 | - | - |

504 CBS, CBS-KNAW Fungal Biodiversity Centre, Utrecht, the Netherlands; FMR, Facultat de Medicina, Universitat Rovira i Virgili,
505 Reus, Spain; UTHSC, Fungus Testing Laboratory at the University of Texas Health Science Center, San Antonio, USA; ^T, Ex-type
506 strain. BAL, bronchoalveolar lavage fluid specimen; CSF, cerebrospinal fluid. Accession numbers in bold represent sequences
507 generated in this study.
508

509 **Table 2** Results of *in vitro* antifungal susceptibility testing of the 92 clinical isolates included in the study.

| Genus | Species (N° of isolates tested) | MIC/MEC parameter | Result (µg/ml) for: | | | | | | | | |
|---------------------|--|-------------------|---------------------|----------|---------|----------|------------|-----------|---------|------------|------------|
| | | | AMB | 5FC | VRC | PSC | ITC | TBF | CFG | AFG | MFG |
| <i>Cladosporium</i> | <i>C. cladosporioides</i> complex (57) | Range | 0.06-2 | 0.06->32 | 0.25-16 | <0.03-1 | <0.03-2 | <0.03-4 | 0.125-8 | 0.03-0.5 | 0.03-0.5 |
| | | GM | 0.73 | 1.20 | 1.65 | 0.40 | 0.34 | 0.12 | 2.78 | 0.19 | 0.11 |
| | | MIC ₉₀ | 1 | 4 | 4 | 0.5 | 0.5 | 1 | 8 | 0.5 | 0.25 |
| | <i>C. tenuissimum</i> (9) | Range | 0.5-1 | 1->16 | 1-4 | 0.25-0.5 | 0.25-0.5 | 0.06-1 | 4-8 | 0.125-0.5 | 0.125-0.25 |
| | | GM | 0.93 | 2.72 | 1.85 | 0.37 | 0.29 | 0.18 | 4.67 | 0.37 | 0.15 |
| | | MIC ₉₀ | 1.00 | 4.00 | 2.00 | 0.50 | 0.50 | 0.25 | 8.00 | 0.50 | 0.25 |
| | <i>C. subuliforme</i> (5) | Range | 1-2 | 0.25-2 | 0.25-2 | 0.25-0.5 | 0.25 | 0.06-1 | 4-8 | 0.06-0.5 | 0.06-0.25 |
| | | GM | 1.15 | 1.00 | 0.66 | 0.29 | 0.25 | 0.28 | 5.28 | 0.16 | 0.12 |
| | | MIC ₉₀ | 1.00 | 2.00 | 1.00 | 0.25 | 0.25 | 1.00 | 8.00 | 0.25 | 0.13 |
| | <i>C. pseudocladosporioides</i> (4) | Range | 0.5-1 | 0.5-1 | 2-4 | 0.25-0.5 | 0.5-1 | 0.03-2 | 0.25-8 | 0.03-0.25 | 0.03-0.125 |
| | | GM | 0.59 | 0.71 | 2.38 | 0.42 | 0.59 | 0.21 | 2.38 | 0.15 | 0.07 |
| | | MIC ₉₀ | - | - | - | - | - | - | - | - | - |
| | <i>C. cladosporioides</i> (3) | Range | 0.5-1 | 1-2 | 0.5-16 | 0.25-1 | 0.25-0.5 | 0.5-2 | 1-4 | 0.125-0.25 | 0.125 |
| | | GM | 0.79 | 1.26 | 1.59 | 0.40 | 0.31 | 1.00 | 2.00 | 0.16 | 0.13 |
| | | MIC ₉₀ | - | - | - | - | - | - | - | - | - |
| | <i>C. funiculosum</i> (3) | Range | 0.06-1 | 0.5-1 | 0.5-2 | 0.25-0.5 | 0.125-0.25 | 0.03-0.06 | 4 | 0.06-0.25 | 0.06-0.125 |
| | | GM | 0.31 | 0.63 | 1.00 | 0.31 | 0.20 | 0.04 | 4.00 | 0.12 | 0.08 |
| | | MIC ₉₀ | - | - | - | - | - | - | - | - | - |
| | <i>C. angustisporum</i> (1) | Range | 1.00 | 1.00 | 4.00 | 0.50 | 0.50 | 2.00 | 4.00 | 0.13 | 0.06 |
| | | GM | - | - | - | - | - | - | - | - | - |

| | | | | | | | | | | |
|---------------------------------|-------------------|-------------|----------|--------|----------|----------|-------------|---------|----------|------------|
| | MIC ₉₀ | - | - | - | - | - | - | - | - | - |
| <i>C. asperulatum</i> (1) | Range | 1 | 0.25 | 2 | 0.25 | 0.5 | 0.03 | 8 | 0.25 | 0.125 |
| | GM | - | - | - | - | - | - | - | - | - |
| | MIC ₉₀ | - | - | - | - | - | - | - | - | - |
| <i>C. flabelliforme</i> (1) | Range | 2 | 2 | 2 | 0.5 | 0.25 | 0.03 | 4 | 0.25 | 0.125 |
| | GM | - | - | - | - | - | - | - | - | - |
| | MIC ₉₀ | - | - | - | - | - | - | - | - | - |
| <i>C. perangustum</i> (1) | Range | 0.5 | 4 | 4 | 0.5 | 0.5 | 0.03 | 4 | 0.125 | 0.06 |
| | GM | - | - | - | - | - | - | - | - | - |
| | MIC ₉₀ | - | - | - | - | - | - | - | - | - |
| <i>Cladosporium</i> sp. (29) | Range | 0.125-2 | 0.06->16 | 0.25-8 | <0.03-1 | <0.03-2 | <0.03-4 | 0.125-8 | 0.03-0.5 | 0.03-0.5 |
| | GM | 0.67 | 1.10 | 1.73 | 0.43 | 0.36 | 0.09 | 2.00 | 0.18 | 0.10 |
| | MIC ₉₀ | 1.00 | 4.00 | 4.00 | 0.50 | 0.50 | 1.00 | 8.00 | 0.50 | 0.25 |
| <i>C. herbarum</i> complex (14) | Range | <0.03-2 | 0.5->16 | 0.5-8 | 0.06-0.5 | 0.06-1 | <0.03-0.125 | 0.125-8 | 0.06-1 | 0.06-0.5 |
| | GM | 0.18 | 2.97 | 1.81 | 0.37 | 0.35 | 0.05 | 0.67 | 0.23 | 0.15 |
| | MIC ₉₀ | 1 | 8 | 4 | 0.5 | 0.5 | 0.125 | 2 | 0.5 | 0.5 |
| <i>C. allicinum</i> (3) | Range | <0.03-0.125 | 2-4 | 2-4 | 0.5 | 0.25-0.5 | 0.03-0.06 | 1.00 | 0.25-0.5 | 0.125-0.25 |
| | GM | 0.05 | 2.52 | 3.17 | 0.50 | 0.40 | 0.05 | 1.00 | 0.31 | 0.20 |
| | MIC ₉₀ | - | - | - | - | - | - | - | - | - |
| <i>C. ramotenellum</i> (3) | Range | 1-2 | 4->16 | 1-2 | 0.5 | 0.5-1 | <0.03-0.125 | 0.5-8 | 0.25-1 | 0.125-0.5 |
| | GM | 1.26 | 4.00 | 1.59 | 0.50 | 0.63 | 0.05 | 2.00 | 0.40 | 0.20 |
| | MIC ₉₀ | - | - | - | - | - | - | - | - | - |

| | | | | | | | | | | |
|---------------------------------------|-------------------|----------|--------|--------|----------|----------|-------------|-----------|------------|------------|
| <i>C. herbarum</i> (1) | Range | 0.06 | 8 | 2 | 0.5 | 0.5 | 0.03 | 0.5 | 0.125 | 0.125 |
| | GM | - | - | - | - | - | - | - | - | - |
| | MIC ₉₀ | - | - | - | - | - | - | - | - | - |
| <i>C. macrocarpum</i> (1) | Range | 0.5 | 2 | 1 | 0.25 | 0.5 | 0.125 | 1 | 0.125 | 0.5 |
| | GM | - | - | - | - | - | - | - | - | - |
| | MIC ₉₀ | - | - | - | - | - | - | - | - | - |
| <i>C. subinflatum</i> (1) | Range | 0.5 | 0.5 | 4 | 0.5 | 0.5 | 0.03 | 0.5 | 0.5 | 0.25 |
| | GM | - | - | - | - | - | - | - | - | - |
| | MIC ₉₀ | - | - | - | - | - | - | - | - | - |
| <i>Cladosporium</i> sp. (5) | Range | 0.06-0.5 | 2-4 | 0.5-8 | 0.06-0.5 | 0.06-0.5 | <0.03-0.125 | 0.125-0.5 | 0.06-0.5 | 0.06-0.125 |
| | GM | 0.11 | 2.30 | 1.32 | 0.25 | 0.19 | 0.05 | 0.29 | 0.14 | 0.08 |
| | MIC ₉₀ | 1.00 | 4.00 | 4.00 | 0.50 | 0.50 | 1.00 | 8.00 | 0.50 | 0.25 |
| <i>C. sphaerospermum</i> complex (17) | Range | 0.125-2 | 0.06-4 | 0.5-16 | 0.06-4 | 0.25->16 | <0.03-1 | 0.06-4 | <0.03-1 | 0.06-1 |
| | GM | 1.13 | 1.13 | 1.70 | 0.64 | 1.13 | 0.06 | 1.27 | 0.15 | 0.13 |
| | MIC ₉₀ | 2 | 2 | 8 | 2 | 32 | 0.5 | 4 | 0.25 | 0.125 |
| <i>C. halotolerans</i> (13) | Range | 0.125-2 | 0.06-4 | 0.5-2 | 0.06-1 | 0.25-2 | <0.03-1 | 0.06-4 | <0.03-0.25 | 0.06-0.125 |
| | GM | 1.00 | 0.90 | 1.11 | 0.47 | 0.56 | 0.08 | 1.00 | 0.11 | 0.10 |
| | MIC ₉₀ | 2.00 | 2.00 | 2.00 | 1.00 | 2.00 | 1.00 | 4.00 | 0.25 | 0.13 |
| <i>C. sphaerospermum</i> (3) | Range | 1-2 | 2-4 | 8-16 | 2-4 | >16 | <0.03-0.125 | 2-4 | 0.25-1 | 0.125-1 |
| | GM | 1.59 | 2.52 | 10.08 | 2.52 | >16 | 0.03 | 3.17 | 0.50 | 0.40 |
| | MIC ₉₀ | - | - | - | - | - | - | - | - | - |
| <i>Cladosporium</i> sp. (1) | Range | 2 | 2 | 2 | 0.5 | 0.5 | <0.03 | 2 | 0.25 | 0.125 |
| | GM | - | - | - | - | - | - | - | - | - |

| | | | | | | | | | | |
|---|-----------------------------------|-------------------|---------|----------|---------|---------|-----------|------------|---------|--------------------|
| | | MIC ₉₀ | - | - | - | - | - | - | - | - |
| | Overall (88) | Range | <0.03-2 | 0.06->16 | 0.25-16 | <0.03-4 | <0.03->16 | <0.03-4 | 0.06-8 | <0.03-1 0.03-1 |
| | | GM | 0.64 | 1.37 | 1.68 | 0.43 | 0.43 | 0.09 | 1.91 | 0.19 0.12 |
| | | MIC ₉₀ | 2.00 | 4.00 | 4.00 | 0.50 | 1.00 | 1.00 | 8.00 | 0.50 0.25 |
| <i>Toxicocladosporium T. irritans</i> (2) | | Range | 0.5-1 | 0.25-2 | 0.25 | 0.25-1 | 0.5 | <0.03-0.06 | 0.125-2 | 0.06-0.25 0.06-0.5 |
| | | GM | 0.71 | 0.71 | 0.25 | 0.50 | 0.50 | 0.03 | 0.50 | 0.12 0.17 |
| | | MIC ₉₀ | - | - | - | - | - | - | - | - |
| | <i>Toxicocladosporium</i> sp. (1) | Range | 0.5 | 0.125 | 0.25 | 0.125 | 0.125 | <0.03 | 1 | 0.125 0.06 |
| | | GM | - | - | - | - | - | - | - | - |
| | | MIC ₉₀ | - | - | - | - | - | - | - | - |
| | Overall (3) | Range | 0.5-1 | 0.125-2 | 0.25 | 0.125-1 | 0.125-0.5 | <0.03-0.06 | 0.125-2 | 0.06-0.25 0.06-0.5 |
| | | GM | 0.63 | 0.40 | 0.25 | 0.31 | 0.31 | 0.02 | 0.63 | 0.12 0.12 |
| | | MIC ₉₀ | - | - | - | - | - | - | - | - |
| <i>Penidiella</i> | <i>Penidiella</i> sp. (1) | Range | 2 | 0.06 | 0.125 | 0.06 | >0.03 | >0.03 | 0.25 | 0.25 0.25 |
| | | GM | - | - | - | - | - | - | - | - |
| | | MIC ₉₀ | - | - | - | - | - | - | - | - |

510 GM, geometric mean; MIC₉₀, drug concentration that inhibited 90% of the isolates, shown only for species with ≥5 isolates. AMB,
 511 amphotericin B; 5FC, flucytosine; VRC, voriconazole; PSC, posaconazole; ITC, itraconazole; CFG, caspofungin; AFG,
 512 anidulafungin; MFG, micafungin; TRB, terbinafine.^a, these columns include MEC data.

513 **Figure 1** Maximum likelihood tree inferred from combined ITS, *EF-1 α* and *Act*
514 sequences of *Cladosporium* isolates. Branch lengths are proportional to
515 phylogenetic distance. ML bootstrap support (BS) values of $\geq 70\%$ and posterior
516 probability (PP) values of ≥ 0.95 are shown above the branches. Thickened
517 branches indicate BS=100% and PP=1.00. *Cercospora beticola* (CBS 116456)
518 was used to root the tree. Type strains are indicated in bold. CBS, CBS-KNAW
519 Fungal Biodiversity Centre, Utrecht, the Netherlands; FMR, Facultat de
520 Medicina i Ciències de la Salut, Reus, Spain; UTHSC, Fungus Testing
521 Laboratory at the University of Texas Health Science Center, San Antonio,
522 USA.

523

524 **Figure 2** Conidiophores and conidia: (a to c) *C. cladosporioides* complex. (d to
525 f) *C. herbarum* complex. (g to i) *C. sphaerospermum* complex. (j to l)
526 *Toxicocladosporium* spp. White bars, 10 μm ; black bars, 5 μm .

527

528 **Figure 3** Maximum likelihood tree inferred from combined ITS and LSU
529 sequences of *Toxicocladosporium* isolates. Branch lengths are proportional to
530 phylogenetic distance. ML bootstrap support (BS) values of $\geq 70\%$ and posterior
531 probability (PP) values of ≥ 0.95 are shown above the branches. Thickened
532 branches indicate BS=100% and PP=1.00. *Cercospora beticola* (CBS 116456)
533 and *Cercospora olivascens* (CBS 253.67) were used to root the tree. Type
534 strains are indicated in bold. CBS-KNAW, Fungal Biodiversity Centre culture
535 collection, the Netherlands; UTHSC, Fungus Testing Laboratory at the
536 University of Texas Health Science Center, San Antonio, USA.





